George A J, Tutt A L, Stevenson F K
J Immunol. 1987 Jan 15;138(2):628-34.
Immunization of BALB/c mice with idiotypic IgM rescued by hybridization from the syngeneic BCL1 lymphoma protects specifically against challenge with tumor cells, with 83% surviving greater than 100 days compared with controls (38 +/- 10 days). Spleens from long-term survivors (greater than 6 mo) with no macroscopically visible tumor, when examined with anti-idiotypic antibody, showed a range of apparently dormant tumor with BCL1 cells present at 2 to 50% of total. A spectrum of protection against tumor resulted from immunization, and tumor emerging in the period 53 to 173 days postpassage was investigated for expression of idiotype. It was found that cells from individual mice expressed variable amounts of idiotypic IgM at the cell surface, although it was always detectable in the intracellular compartment. Unlike typical BCL1 cells, tumor cells developing in immune spleens often secreted little idiotypic IgM either in vitro or in vivo. This modulation of expression and secretion of idiotype was detected even in the apparent absence of serum anti-idiotypic antibody. On passage of spleen cells from the long-term survivors into naive animals, BCL1 tumor developed and killed the recipients in a way indistinguishable from routine tumor passage. These tumor cells, however, both expressed and secreted IgM of the same idiotype as the original tumor. It appears therefore that tumor development in immunized mice is suppressed by a process that includes modulation but not selection of the tumor cell idiotypic determinants. Analysis of possible mechanisms of suppression revealed the presence of cytotoxic anti-idiotypic antibody at variable levels in sera of immunized mice, and splenic T cells that proliferated specifically in response to idiotypic IgM. Only low levels of cytotoxic T cells were found. Passive transfer studies demonstrated a major role for antibody in protection against tumor, with no significant enhancement by immune lymphocytes.
用从同基因BCL1淋巴瘤通过杂交拯救的独特型IgM对BALB/c小鼠进行免疫,可特异性保护小鼠免受肿瘤细胞攻击,与对照组(38±10天)相比,83%的小鼠存活超过100天。对无肉眼可见肿瘤的长期存活者(超过6个月)的脾脏进行抗独特型抗体检测时,发现一系列明显处于休眠状态的肿瘤,其中BCL1细胞占总数的2%至50%。免疫可产生一系列抗肿瘤保护作用,对传代后53至173天出现的肿瘤进行独特型表达研究。发现来自个体小鼠的细胞在细胞表面表达可变数量的独特型IgM,尽管在细胞内区室中总是可检测到。与典型的BCL1细胞不同,在免疫脾脏中产生的肿瘤细胞在体外或体内通常很少分泌独特型IgM。即使在明显没有血清抗独特型抗体的情况下,也能检测到独特型表达和分泌的这种调节。将长期存活者的脾细胞接种到未免疫的动物体内时,BCL1肿瘤发展并杀死受体,其方式与常规肿瘤接种无异。然而,这些肿瘤细胞表达并分泌与原始肿瘤相同独特型的IgM。因此,免疫小鼠中的肿瘤发展似乎受到一个过程的抑制,该过程包括对肿瘤细胞独特型决定簇的调节而非选择。对可能的抑制机制分析显示,免疫小鼠血清中存在不同水平的细胞毒性抗独特型抗体,以及对独特型IgM特异性增殖的脾T细胞。仅发现低水平的细胞毒性T细胞。被动转移研究表明抗体在抗肿瘤保护中起主要作用,免疫淋巴细胞无明显增强作用。